raltitrexed + docetaxel

Raltitrexed + docetaxel is an investigational combination of two chemotherapeutic agents, each with distinct mechanisms of action. Raltitrexed is a quinazoline folate analogue that selectively inhibits thymidylate synthase, an enzyme essential for DNA synthesis, leading to DNA fragmentation and cell death. It acts as an antimetabolite and is S-phase specific. Docetaxel is a taxane-class agent that promotes microtubule assembly while inhibiting their depolymerization, resulting in cell cycle arrest and apoptosis. The rationale for combining these drugs lies in their non-overlapping mechanisms and potential for synergistic antitumor effects. This combination has been explored preclinically and clinically (in early phase studies) primarily in solid tumors such as colorectal cancer, but it does not have established approval or widespread clinical use as a fixed regimen[3][6][2].

Other names

raltitrexed + docetaxel